Ipca Laboratories Peer Comparison

NSE: IPCALAB | BSE: 524494

₹1,884.00

₹-15.70 (-0.83%)

As on 13-Nov-2026IST

Market cap

₹47,828 Cr

Revenue (TTM)

₹10,479 Cr

P/E Ratio

34.1

P/B Ratio

5.5

Div. Yield

0.3 %

Edit

	Ipca Laboratories	Zydus Lifesciences	Dr. Reddy'S Labs	Mankind Pharma	Aurobindo Pharma
Market cap (₹ Cr)	47,828	1,18,803	1,15,017	1,09,622	1,05,237
Revenue (₹ Cr)	10,479	30,378	33,097	15,379	36,913
Net Profit (₹ Cr)	1,487.80	4,159.00	2,759.70	2,249.69	3,993.05
Net Margin (%)	13.98	13.20	8.03	14.32	10.61
RoE (%)	17.20	16.61	7.30	13.86	10.51
Price to Earnings	34.11	28.42	41.08	48.88	26.37
Price-To-Book	5.51	4.27	2.96	6.23	2.67

Income Statement (₹ Cr)

	Ipca Laboratories	Zydus Lifesciences	Dr. Reddy'S Labs	Mankind Pharma	Aurobindo Pharma
Operating Revenue	10,479.02	30,378.10	33,097.40	15,378.58	36,912.88
Total Income	10,643.24	31,504.60	34,352.50	15,705.47	37,650.01
Total Expenditure	8,118.81	22,828.30	28,236.90	11,301.83	29,349.95
EBITDA	2,360.21	7,549.80	4,860.50	4,076.75	7,562.93
Depreciation	440.05	2,027.20	2,141.40	907.11	1,961.27
EBIT	1,920.16	5,522.60	2,719.10	3,169.64	5,601.66
Interest	62.27	595.90	450.40	513.87	394.85
Other Income	164.22	1,126.50	1,255.10	326.89	737.13
Exceptional Items	-52.43	-499.30	0.00	-129.75	-105.51
Profit before Tax	1,969.68	5,553.90	3,523.80	2,852.91	5,838.43
Provision for Tax	481.88	1,394.90	764.10	603.22	1,845.38
Profit after Tax	1,487.80	4,159.00	2,759.70	2,249.69	3,993.05

	Ipca Laboratories	Zydus Lifesciences	Dr. Reddy'S Labs	Mankind Pharma	Aurobindo Pharma
Shareholder's Funds	8,678.33	27,817.30	38,807.00	17,582.22	39,399.90
Minority Interest	-81.59	-101.90	40.20	-20.87	3.68
Non-Current Liabilities	552.33	7,260.60	3,074.90	5,214.33	2,689.12
Current Liabilities	2,406.89	18,023.50	15,430.30	5,884.79	19,667.17
Total Liabilities	12,349.65	50,672.60	56,576.70	27,754.83	58,196.15

	Ipca Laboratories	Zydus Lifesciences	Dr. Reddy'S Labs	Mankind Pharma	Aurobindo Pharma
Non-Current Assets	5,545.08	36,142.90	26,891.10	20,096.89	26,331.59
Current Assets	6,923.89	18,433.50	29,732.20	7,956.27	33,958.66
Total Assets	12,349.65	50,672.60	56,576.70	27,754.83	58,196.15
Total Debt*	703.94	11,769.50	7,734.10	6,021.78	7,676.20
Net Current Assets	4,517.00	410.00	14,301.90	2,071.48	14,291.49
Contingent Liabilities	249.19	989.90	336.14	924.77	1,358.37

	Ipca Laboratories	Zydus Lifesciences	Dr. Reddy'S Labs	Mankind Pharma	Aurobindo Pharma
Cash From Operating Activities	1,141.97	2,116.60	5,673.70	3,121.29	5,526.37
Cash Flow from Investing Activities	-246.77	-8,296.10	-6,549.30	-196.42	-3,458.61
Cash from Financing Activities	-753.53	5,806.90	829.00	-2,952.69	-1,269.15
Net Cash Inflow / Outflow	141.67	-372.60	-46.60	-27.82	798.61

	Ipca Laboratories	Zydus Lifesciences	Dr. Reddy'S Labs	Mankind Pharma	Aurobindo Pharma
ROCE (%)	19.41	21.39	13.75	13.24	12.76
ROE (%)	17.20	16.61	7.30	13.86	10.51
ROA (%)	11.72	8.11	4.93	7.79	6.99
EBIT Margin (%)	18.32	18.18	8.22	20.61	15.18
Net Margin (%)	13.98	13.20	8.03	14.32	10.61
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Ipca Laboratories	Zydus Lifesciences	Dr. Reddy'S Labs	Mankind Pharma	Aurobindo Pharma
Revenue Growth (%)	11.99	24.02	-3.53	13.53	13.53
EBIT Growth (%)	32.31	-16.48	-58.47	31.59	13.09
Net Profit Growth (%)	72.79	-16.41	-51.77	27.79	15.82
EPS Growth (%)	46.57	-10.25	-51.50	34.22	19.29
Book Value Growth (%)	16.05	13.19	12.99	13.74	16.04

	Ipca Laboratories	Zydus Lifesciences	Dr. Reddy'S Labs	Mankind Pharma	Aurobindo Pharma
Price / Earnings	33.22	26.17	41.05	46.67	26.02
Price / Book Value	5.51	4.27	2.96	6.23	2.67
Dividend Yield (%)	0.32	0.08	0.58	0.04	0.22
EV/EBITDA	20.06	16.34	23.81	27.87	13.53
Market Cap (₹ Cr)	40,668.17	87,643.18	1,04,763.81	82,801.75	75,689.14

	Ipca Laboratories	Zydus Lifesciences	Dr. Reddy'S Labs	Mankind Pharma	Aurobindo Pharma
Debt to Equity	0.01	0.15	0.00	0.17	0.02
Short term debt to equity ratio	0.05	0.16	0.16	0.04	0.16
Current Ratio	2.88	1.02	1.93	1.35	1.73
Quick Ratio	1.66	0.64	1.40	0.95	1.06
Interest Coverage	32.63	10.32	8.82	6.55	15.79

	Ipca Laboratories	Zydus Lifesciences	Dr. Reddy'S Labs	Mankind Pharma	Aurobindo Pharma
Debtors to sales (%)	22.86	14.42	30.64	14.17	20.44
Asset Turnover	0.83	0.59	0.59	0.53	0.65
Receivable days	73.75	33.55	103.79	39.93	33.71
Inventory Days	100.11	33.80	79.94	51.78	59.32
Payable days	131.14	149.82	84.78	111.46	148.20
Cash Conversion Cycle	42.73	-82.46	98.95	-19.75	-55.17

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.